Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-14
2010-10-19
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S423000, C514S460000, C514S548000
Reexamination Certificate
active
07816347
ABSTRACT:
A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).
REFERENCES:
patent: 4049495 (1977-09-01), Endo et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4681893 (1987-07-01), Roth
patent: 4739073 (1988-04-01), Kathawala
patent: 4749688 (1988-06-01), Haslanger et al.
patent: 4925852 (1990-05-01), Kesseler et al.
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5082859 (1992-01-01), Festal et al.
patent: 5134157 (1992-07-01), Laruelle et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5677297 (1997-10-01), Waldeck et al.
patent: 5681966 (1997-10-01), Cai et al.
patent: 5783573 (1998-07-01), Rozsa et al.
patent: 5952327 (1999-09-01), Waldeck et al.
patent: 6028075 (2000-02-01), Pines et al.
patent: 6455574 (2002-09-01), Buch
patent: 6482820 (2002-11-01), Wilkins et al.
patent: 6777443 (2004-08-01), Fink
patent: 7045653 (2006-05-01), Dack et al.
patent: 2002/0049237 (2002-04-01), Newton et al.
patent: 2002/0183260 (2002-12-01), Fink
patent: 2003/0008904 (2003-01-01), Buch
patent: 2003/0040512 (2003-02-01), Rozsa et al.
patent: 2004/0048906 (2004-03-01), Buch et al.
patent: 2004/0092573 (2004-05-01), Robl et al.
patent: 2004/0162345 (2004-08-01), Berger et al.
patent: 2004/0176393 (2004-09-01), Newton et al.
patent: 2004/0192584 (2004-09-01), McMahon et al.
patent: 2004/0235754 (2004-11-01), Fink
patent: 2004/0266698 (2004-12-01), Fink
patent: 2005/0020607 (2005-01-01), Newton et al.
patent: 2005/0038012 (2005-02-01), Eerden et al.
patent: 0 254 032 (1988-01-01), None
patent: 0 733 642 (1996-09-01), None
patent: 0 830 863 (1998-03-01), None
patent: 0 916 679 (1999-05-01), None
patent: WO 99/11259 (1999-03-01), None
patent: WO 99/47138 (1999-09-01), None
patent: WO 00/48601 (2000-08-01), None
patent: WO 01/03699 (2001-01-01), None
patent: WO 02/092622 (2002-11-01), None
patent: WO 02/094176 (2002-11-01), None
patent: WO 03/027091 (2003-04-01), None
patent: WO 03/059939 (2003-07-01), None
patent: WO 2004/082636 (2004-09-01), None
patent: WO 2005/030795 (2005-04-01), None
Dessi Fulgheri et al. “The natriuretic peptide system in obesity- related hypertension: new pathophysiological aspects”, Journal of Nephrology, vol. 11, No. 6, 1998, pp. 296-299.
Tabrizchi, “SLV 306 Solvay”, Current Opinion in Investigational Drugs, 2003, vol. 4, No. 3, pp. 329-332.
Graul, “Annual Update 2003: Cardiovascular Drugs”, Drugs of the Future, Barcelona, ES, 2003, vol. 28, No. 6, pp. 565-585.
Stella, “Prodrugs as therapeutics”, Expert Opinion, Ther. Patents, 2004, vol. 14, No. 3, pp. 277-280.
Ettmayer et al., “Lessons learned from marketed and investigational prodrugs”, Journal of Medicinal Chemistry, 2004, vol. 47, No. 10, pp. 2393-2404.
Sum et al., “Prodrugs of CL316243: A Selective β3-Adrenergic Receptor Agonist for Treating Obesity and Diabetes”, Bioorganic & Medicinal Chemistry Letters, 1999, vol. 9, pp. 1921-1926.
Yoshimura et al. “Preparation of 1 Acyloxyethyl Esters of 7-[2-(2-Aminothiazol-4-yl)Acetamido]-3-[[[1-(2-Dimethylaminoethyl)-1H-Tetrazol-5-YL]Thio]-Methyl]Ceph-3-EM-4- Carboxylic Acid (CEFOTIAM) and their Oral Absorption in Mice”, The Journal of Antibiotics, 1986, vol. 39, No. 9, pp. 1329-1342.
Kubo et al. “Nonpeptide angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Potential Prodrugs of Benzimidazole-7-carboxylic Acids1” J. Med. Chem., 1993, vol. 36, No, 16, pp. 2343-2349.
European Search Report dated Mar. 1, 2006 (nine (9) pages).
Koopman Paulus Antonius Remigius
Straub Matthias
Witte Klaus
Ziegler Dieter
Crowell & Moring LLP
Javanmard Sahar
Solvay Pharmaceuticals GmbH
Wang Shengjun
LandOfFree
Pharmaceutical compositions comprising NEP-inhibitors,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising NEP-inhibitors,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising NEP-inhibitors,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211733